COMMUNIQUÉS West-GlobeNewswire

-
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
01/04/2025 -
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
01/04/2025 -
electroCore to Participate at the Needham Virtual Healthcare Conference
01/04/2025 -
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
01/04/2025 -
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
01/04/2025 -
FeraMAXᴹᴰ est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis dix années consécutives
01/04/2025 -
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare
01/04/2025 -
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year
01/04/2025 -
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
01/04/2025 -
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
01/04/2025 -
Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety
01/04/2025 -
Lantern Taps Industry Veteran for Labor, Union & Trust
01/04/2025 -
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
01/04/2025 -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2025 -
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
01/04/2025 -
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
01/04/2025 -
Scientific Industries to Host Fiscal Year 2024 Financial Results Investor Call on April 1, 2025
01/04/2025 -
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
01/04/2025 -
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
01/04/2025
Pages